- Home
- BRNS vs ADVM Comparison
BRNS vs ADVM Comparison
Compare BRNS & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- ADVM
- Stock Information
- Founded
- BRNS 2016
- ADVM 2006
- Country
- BRNS United Kingdom
- ADVM United States
- Employees
- BRNS N/A
- ADVM N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRNS Health Care
- ADVM Health Care
- Exchange
- BRNS Nasdaq
- ADVM Nasdaq
- Market Cap
- BRNS 40.0M
- ADVM 47.4M
- IPO Year
- BRNS 2021
- ADVM 2014
- Fundamental
- Price
- BRNS $0.92
- ADVM $2.42
- Analyst Decision
- BRNS Strong Buy
- ADVM Strong Buy
- Analyst Count
- BRNS 1
- ADVM 5
- Target Price
- BRNS $3.00
- ADVM $23.80
- AVG Volume (30 Days)
- BRNS 18.8K
- ADVM 202.7K
- Earning Date
- BRNS 08-07-2025
- ADVM 08-11-2025
- Dividend Yield
- BRNS N/A
- ADVM N/A
- EPS Growth
- BRNS N/A
- ADVM N/A
- EPS
- BRNS N/A
- ADVM N/A
- Revenue
- BRNS $14,969,000.00
- ADVM $1,000,000.00
- Revenue This Year
- BRNS N/A
- ADVM N/A
- Revenue Next Year
- BRNS N/A
- ADVM $18.82
- P/E Ratio
- BRNS N/A
- ADVM N/A
- Revenue Growth
- BRNS 4381.74
- ADVM N/A
- 52 Week Low
- BRNS $0.64
- ADVM $1.78
- 52 Week High
- BRNS $1.58
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- BRNS 50.69
- ADVM 46.41
- Support Level
- BRNS $0.83
- ADVM $2.34
- Resistance Level
- BRNS $0.95
- ADVM $2.60
- Average True Range (ATR)
- BRNS 0.05
- ADVM 0.21
- MACD
- BRNS -0.01
- ADVM 0.02
- Stochastic Oscillator
- BRNS 45.35
- ADVM 28.78
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.